哌啶系列-----医药中间体
中间体Piperidine-2-carboxylic acid
$ \3 h% X( `' H5 r) Q3 _
/ `9 f/ n* W- i' p4 m4 n2-哌啶甲酸
( J! L0 G- |' C0 x1 w/ L/ X& y535-75-1% o& J+ X, m9 j+ ~
≥98%
, { n& X3 L: F/ C3 ~0 L/ _ C中间体Piperidine-3-carboxylic acid8 p8 t" G: l1 N C) r9 N( D
3-哌啶甲酸/ j. b; m8 o. z9 b
498-95-3
, k% l5 f' G6 B7 }9 o6 t≥97%
a) ^1 g9 t" l" Y中间体Piperidine-4-carboxylic acid0 u, U- U: W, @2 ~4 m
2 g2 L& E6 i. N) D, h
4-哌啶甲酸
8 g! \/ W8 }" B' _498-94-20 b6 S' b( T9 e1 x
≥99%
3 J7 |5 U, X! E7 N* X
! L8 s& x4 [! f9 [N -Boc-2-哌啶甲酸CAS: 98303-20-9
; y1 i2 Y8 l; }& L' y
$ }# F% n( N+ R& [2 p1 nN-BOC-3-哌啶甲酸84358- 12-36 }9 k) ?$ o( b; z8 T/ C
N-BOC- Piperidine-4-carboxylic acid
3 ~. I4 a k9 z5 ?9 f% L9 UN-BOC-4-哌啶甲酸 84358-13-4
7 h! l: M' V0 K- t( f; G) G- J! v. c$ s
1 O+ f4 j+ l1 {7 m
≥98%
& r1 H" m7 |2 r& m中间体4-Piperidinopiperidine
( `0 X+ Z [9 ], q. O' S1 }
$ |" Z1 d' C$ |; e& L6 s4-哌啶基哌啶 4897-50-1& C W- A( L( {/ Z/ n* M
≥ 98%
! e* d, \, X! Q- t8 R# w中间体 Benzoyl piperidine 苯甲酰哌啶 z0 W* j( j- l- R/ Q3 o( n/ ?( W2 E+ H
776-75-0
, J! q) H4 g3 T≥ 98%
4 o6 I8 l; A- l* Z中间体1-methyl-4-Chloropiperidine
% y* Y9 d7 P1 G# y. H0 F2 XN-甲基-4-氯哌啶
) w" l4 Y1 b* B7 O( z7 E: h5570-77-4
7 T9 r4 M. h: n" F1 T1 h≥99%" n' c1 m+ E5 g& k6 z R
中间体 Methyl Piperidine-2-carboxylate" T7 W8 B6 I) u( K
2-哌啶甲酸甲酯（盐酸盐）3 x5 b0 I, x9 \% y( W/ X6 Z H8 k
41994-45-0
1 s! o& q0 Y" G& ]' ?3 Y% h≥99%5 M/ O3 n1 A5 G
哌啶-2-羧酸甲酯
3 b7 F- ^$ M6 I( _$ A3 ^8 c* e中间体 Methyl Piperidine-3-carboxylate
' i# e* g) R- {. |3-哌啶甲酸甲酯（盐酸盐） 50585-89-2
1 H+ x5 V L: f& i/ l, \9 L; j B≥99% - W8 u2 S: K& o, t) A
Methyl nipecotate
/ N7 ` @ b- V, y' d5 {6 P t中间体 Methyl Piperidine-4-carboxylate
9 e8 y1 `0 D( F( f, B+ ^! ^4-哌啶甲酸甲酯（盐酸盐） 2971-79-1
, x! Z% x/ n6 N8 z+ T% U& N, ~ U$ U≥99%/ z' ^1 r8 B; _1 M
哌啶-4-羧酸甲酯Methyl isonipecotate
* s6 Q; ~* x9 t2 {; u' U4 I$ `2 e中间体 Ethyl piperidine-2-carboxylate
8 F c4 ?7 ]5 O* K" b) m2-哌啶甲酸乙酯（盐酸盐）+ t* D6 ]" o2 \; E+ S* w+ R' D
15862-72-3
' I [ k( a& \/ D, `≥99%# H+ S' q+ D$ m
哌啶-2-羧酸乙酯
0 w+ x2 e+ M: j, z中间体 Ethyl piperidine-3-carboxylate% U, y- {* z# _: g# K
3-哌啶甲酸乙酯（盐酸盐）
4 }( y3 D' ^/ A G+ W9 j" H5006-62-2
' R, f3 G3 d8 `5 R5 v≥99%# i% e& p( P0 Q5 X3 l* f
哌啶-3-羧酸乙酯
7 L8 C6 V% G5 @0 L/ W中间体 Ethyl piperidine-4-carboxylate
* x8 f$ W$ y6 }: _+ w4-哌啶甲酸乙酯（盐酸盐）. @% b6 m8 t& l! [7 r
1126-09-6& ` M1 E6 @: e7 B6 c
≥99%
1 {3 }, [3 K' Z3 i! E- L, z1 F哌啶-4-羧酸乙酯
8 s- `( y) S( j5 U& O# [中间体 Methyl Piperidine-2-carboxylate; K# p- U, e6 \0 i
2-哌啶甲酸甲酯盐酸盐4 \# c; K$ i7 m; `
≥99%
2 e: i7 Z _# G/ j! W2 {& ~3 `: @中间体 Methyl Piperidine-3-carboxylate. J6 b, j' C/ w B& o- c) o
3-哌啶甲酸甲酯盐酸盐2 O$ Z3 u; v* T9 B% V
≥99%$ W- ~( h, W5 b1 E7 B. u; l, {
中间体 Methyl Piperidine-4-carboxylate! k3 @+ n9 V% H, ^* s: E
4-哌啶甲酸甲酯盐酸盐
) H' n" A* V7 H# X
: D) ]4 f4 [7 s5 \4 C* U" |8 }& }≥99%
\3 _+ p& a5 c3 S4 p中间体 Ethyl piperidine-2-carboxylate
2 l+ K. u4 I5 J8 J1 [/ Q. K, E2-哌啶甲酸乙酯盐酸盐3 O% a! P2 Y; _, u
≥99%
3 I" V' i. N8 r4 ?1 T中间体 Ethyl piperidine-3-carboxylate
0 v3 u8 p3 A( L r3-哌啶甲酸乙酯盐酸盐
6 o! e8 E+ k1 q! d7 s: G" B3 |≥99%
' y. w. P% l4 F9 O8 V) E; a" e中间体 Ethyl piperidine-4-carboxylate/ W' G& Q! G6 |. L# d6 a8 C# L
4-哌啶甲酸乙酯盐酸盐
6 B" k# g3 g9 h+ N≥99%* `# J& O2 V/ S8 z( R
中间体 Methyl 1-methyl Piperidine-2-carboxylate, V9 N* v: M% E8 r: g0 A
1-甲基-2-哌啶甲酸甲酯 30727-18-5( c0 C4 m% ?! _4 z" e" }
≥98%
% H' B" L; ^+ R
. U4 |1 N. K3 k3 gEthyl 1-methylpipecolinate0 z5 U3 N2 H5 B3 l: A
中间体 Methyl 1-methyl Piperidine-3-carboxylate
" V9 v w$ p/ |( r2 V* W: q4 k1-甲基-3-哌啶甲酸甲酯1690-72-8$ D) W3 R) \1 K4 G0 E' q
中间体 Ethyl 1-methyl piperidine-3-carboxylate
% E' s% s3 N) u5 c1-甲基-3-哌啶甲酸乙酯 5166-67-6
4 q' B: u {, R- |4 C≥98%
: ^3 \, s9 C: @) uEthyl 1-methyl piperidine-4-carboxylate
) \8 j' g& C6 i8 W& |% W% W1-甲基-4-哌啶甲酸乙酯
4 n {* T/ Y3 [" V$ u≥98%
# A( x9 \& g* n0 s中间体 1-乙氧羰基甲基-4-哌啶甲酸乙酯
) v: ?1 S6 g3 c7 F4 K中间体 Methyl N-Boc-piperidine-3-carboxylate0 J6 I3 |- C! z- R( T; Z' E3 Q+ k R
N-Boc-3-哌啶甲酸甲酯 148763-41-1
( ?8 h# G& l3 s$ A/ v
, _0 k6 L$ M+ c+ l( o≥98% & A& y& O6 D& t* I+ ~
中间体Methyl N-Boc-piperidine-4-carboxylate 5 \ t* B6 Q5 _# O4 E! M
N-Boc-4-哌啶甲酸甲酯
2 G& Q' ~; U8 G" t1 A2 Q124443-68-12 R* @. c& B3 T8 H# z; G
: C. U3 R5 F# b$ A6 v+ V+ R
≥98%# U7 u( }( h, ]3 w# G- }
中间体Ethyl N-Boc-piperidine-2-carboxylate" Y' L* [8 U6 J8 Z) J5 Y
N-Boc-2-哌啶甲酸乙酯
$ u2 ?3 b) y+ s1 ^362703-48-86 Q' p, G8 T' K: y# Z
≥98%: E5 l+ v) q6 K" p. ^& F$ B5 s0 R
中间体Ethyl N-Boc-piperidine-3-carboxylate
' {: ]% D; ]+ n% E3 M# ]N-Boc-3-哌啶甲酸乙酯
2 p* j2 r2 Y9 I, u/ ?2 k130250-54-3
. T6 y# i' t y≥98%# ]5 ~; B6 _2 s& {
中间体Ethyl N-Boc-piperidine-4-carboxylate. O( p: _7 J$ O$ a
N-Boc-4-哌啶甲酸乙酯8 H' k W. X7 k/ V. Y# y2 i! B
≥98% d3 ^. Y1 _7 y J* |: c
中间体Ethyl (R)-nipecotate" e( }% ^- H6 u4 P
(R)-3-哌啶甲酸乙酯 25137-01-3 ≥99%
1 ]2 y S# Z) YＲ-Nipecotic acid
; F9 r1 f7 E& |8 k# T2 I. v, L$ t25137-00-2: L, }! p3 r0 I8 c1 m6 q8 ?9 ^
中间体Ethyl (S)-nipecotate (S)-3-哌啶甲酸乙酯 37675-18-6
. C3 o1 q" {) v# ?) |≥99%6 B- I6 r) Z1 k: h$ i5 b, _/ P
中间体Ethyl (R)-nipecotate,L-tartrate 0 a$ |) y% T% R: M/ S6 _" Y
(R)-3-哌啶甲酸乙酯-L酒石酸盐1 P5 a$ S; o I* h1 |
167392-57-60 x' E6 b' I9 \4 N" Q- u+ ]
≥99%
- G5 _: p$ v% C, C中间体Ethyl (S)-nipecotate,L-tartrate
6 `0 G* j7 I+ \* G4 E) Z3 Y(S)-3-哌啶甲酸乙酯-D酒石酸盐
2 v7 o! H! u9 h6 f# ^83602-38-43 z! s% a/ n7 b" ?7 |
≥99%
/ t1 g5 D9 S; n* k) Q1 j5 B中间体2-Piperidine carboxamide
( V% [3 R; m. x" ~& ?2-哌啶甲酰胺
$ q0 i; D8 n6 s中间体3-Piperidine carboxamide
# w3 V- m5 S/ @0 f2 w3-哌啶甲酰胺 4138-26-5, P! A) z5 |6 H. I4 R( e
≥98%+ x* @2 L& C1 i2 J
中间体4-Piperidine carboxamide* E0 ]' @* N6 t1 [
4-哌啶甲酰胺 39546-32-2, ?; }. e$ x- v4 j% ~
≥98%
E$ k" e4 v& A/ ]( v) WIsonipecotamide+ |9 G- ?) l. I4 a( f# R4 L8 G$ j
中间体 2-piperidine methanol
4 L5 N' f* x5 z& q. R2-哌啶甲醇( o* ^" e1 p& h( R K5 ~) ]7 L
3433-37-2
; e9 a: T ~! E/ W, E≥98%# x: N) T! w: C9 ?. ~
中间体 3-piperidine methanol
q1 m- f, D6 Q* f7 P# n$ f l3-哌啶甲醇& Y( k# s3 d% A0 p' C5 e0 m
4606-65-9
! q/ j9 K5 `! k$ k. z≥98%# C5 y+ f0 o3 l$ W1 ]
中间体 4-piperidine methanol9 y; h" r+ V9 M* o2 ~
4-哌啶甲醇2 t+ Q: @1 \! f7 |8 F) P) e, D, \
6457-49-4+ f( _% C% g3 S" i0 m- e
≥98%" j: c5 @( d* j5 L J
4-(Hydroxymethyl)piperidine9 R/ S0 x' d4 I7 U3 h$ `
4-羟甲基哌啶
3 E; P# [, i. w5 ^5 Q5 D$ N8 y中间体 1-methyl 4-piperidinemethanol 1-甲基-4-哌啶甲醇
, k) Z0 }. _6 R3 |! p9 Y20691-89-8
7 \1 r- ~" ] x Q6 ~6 G≥98%
. s. N4 Y/ a3 R中间体N-Boc-3-piperidinemethanol. M1 m3 K2 u0 B2 u
N-Boc-3-哌啶甲醇& d7 {1 U' \( P
116574-71-12 m3 m9 l! E: k D# F
≥97%
6 Z/ u2 }4 L3 d* i- _; y1 iN-Boc-4-piperidinemethanol
) o* ~. A# {1 T9 ~* |: n. e! lN-Boc-4-哌啶甲醇7 b0 y7 C; g# r% p$ p: H, X
123855-51-6, p8 D8 P1 X0 x: _9 P
≥97%, W3 x& J6 V! a8 g" L
N-叔丁氧羰基-4-哌啶甲醇+ k# k8 Y6 l/ H
中间体 N-ethoxycarbonyl-4-piperidinemethanol 3 a# w+ ]4 S0 Z2 U- G! L' u6 q
N-乙氧羰基-4-哌啶甲醇. T$ e6 C! E' q3 {
中间体
5 ~6 I( q4 M/ ~2 G& T) t: P' wN-氯基-4-哌啶甲醇
6 k7 M5 C4 _( `6 R≥98%# F. _6 k+ @4 @& J6 B" x
7 U0 o$ L! B* V/ B& l中间体
- e5 z3 d9 ?& c8 e$ rMethyl 1-benzylpiperidine-4-carboxylate
$ h# h5 d- j, A5 z' m* {/ R1-苄基-4-哌啶甲酸甲酯. w# O1 t2 v& S+ V) s) I1 r
≥98%% g% E+ W9 @7 K* ^ H
中间体
* B8 c. j$ r6 d( o1 b4 lEthyl 1-benzylpiperidine-4-carboxylate
" b) q8 M! t: \* O1-苄基-4-哌啶甲酸乙酯
0 {, T, D" O* u0 a4 [2 K2 D24228-40-8.2 E3 O$ w' y3 Z8 [' O8 l8 Q% l9 D- f
≥98%. @: \# ` y7 v9 [4 T9 R
中间体
. }- r. L- p) U4 F& `7 x1-benzyl-4-piperidinemethanol
: ^( @7 C2 _& H; m1-苄基-4-哌啶甲醇- T3 w* N' z/ ]& y4 d7 P
67686-01-5
6 u3 x: c% a+ g# F, i7 i) B4 v% ^8 o- F0 `( @" C5 M
≥98%
6 N2 l3 P0 @2 G8 k. Z) jmsn:yuexiudonghua@hotmail.com///0531-82375879///qq:944796213
